About This Test
Her-2 overexpression in breast carcinoma is associated with shorter disease free interval and shorter overall survival. Her-2 positive breast cancers tend to be more aggressive but treatments that target Her-2 are very effective. Expression of Her-2 protein is an indication for specific therapy with Trastuzumab / Herceptin / Pertuzumab / Neratinib in patients with breast cancer.
Test Parameters (1)
- IMMUNOHISTOCHEMISTRY, HER-2/ERBB 2
Home Collection
✓ Available
Reports Available In
7 Days
Frequently Asked Questions
Outsourced test are being done from Dr. Lal Path Lab. Charges and reporting time is same as of Dr. Lal Path Labs.
Provide a copy of the Histopathology report.
HER-2 (Human Epidermal Growth Factor Receptor 2 / ERBB2) is a protein found on the surface of some cancer cells, most commonly in breast and gastric cancers. IHC testing measures HER-2 expression in tumor tissue and is critical for diagnosis, prognosis, and therapy planning.
TAT Policy
The Turnaround Time (TAT) depends on the following factors:
- Registration date and time
- Type of scan or test
- Scan time or sample collection time
In uncommon circumstances, TAT may be delayed due to test complexity or reasons beyond our control. You will be informed of the estimated TAT at the time of registration.
